Literature DB >> 2839256

Clonal analysis of transplant-associated lymphoproliferations based on the structure of the genomic termini of the Epstein-Barr virus.

M L Cleary1, M A Nalesnik, W T Shearer, J Sklar.   

Abstract

The clonal composition of various transplant-associated lymphoproliferations was assessed by means of Southern blot hybridizations using a DNA probe specific for the fused termini of the Epstein-Barr virus (EBV) genome. A single clonal band representing the joined EBV genomic termini was detected in most biopsies, demonstrating the presence of a monoclonal expansion of B lymphocytes carrying EBV DNA. Different configurations of immunoglobulin gene rearrangements and fused EBV genomic termini were frequently observed in tissues from different biopsy sites in individual patients, confirming the multiclonal origins for these lymphomas. In rare specimens, multiple forms of the joined termini were detected within individual lesions, which appeared polymorphous by histologic methods of analysis and polyclonal by immunologic and immunogenetic methods of analysis. These studies confirm that there is a spectrum of EBV-associated disorders of varying clonal composition that may arise in immunosuppressed organ-allograft recipients. The data are consistent with the proposal that the lymphoproliferations initiate as polyclonal expansions of EBV-carrying B cells, which progress to multiclonal lymphomas in most patients. Detection of homogeneous episomal EBV DNA in most lesions supports a primary role for the virus in the pathogenesis of these disorders.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2839256

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  27 in total

1.  Inhibition of Epstein-Barr virus infection in vitro and in vivo by soluble CR2 (CD21) containing two short consensus repeats.

Authors:  M D Moore; M J Cannon; A Sewall; M Finlayson; M Okimoto; G R Nemerow
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

2.  The detection of Epstein-Barr virus in hairy cell leukemia cells by in situ hybridization.

Authors:  B C Wolf; A W Martin; R S Neiman; A J Janckila; L T Yam; A Caracansi; B A Leav; R Winpenny; D S Schultz; H J Wolfe
Journal:  Am J Pathol       Date:  1990-03       Impact factor: 4.307

3.  Identification of a glucocorticoid-responsive element in Epstein-Barr virus.

Authors:  S R Kupfer; W C Summers
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

Review 4.  Post-transplant lymphoproliferative disorder in children: incidence, prognosis, and treatment options.

Authors:  Albert Faye; Etienne Vilmer
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

5.  Molecular genetic analysis of lymphoid tumors arising after organ transplantation.

Authors:  J Locker; M Nalesnik
Journal:  Am J Pathol       Date:  1989-12       Impact factor: 4.307

Review 6.  Epstein-Barr virus, infectious mononucleosis, and posttransplant lymphoproliferative disorders.

Authors:  M A Nalesnik; T E Starzl
Journal:  Transplant Sci       Date:  1994-09

Review 7.  Epstein-Barr virus infection and associated diseases in children. I. Pathogenesis, epidemiology and clinical aspects.

Authors:  V Schuster; H W Kreth
Journal:  Eur J Pediatr       Date:  1992-10       Impact factor: 3.183

8.  Morphologic and immunophenotypic characterization of a cell line derived from liver tissue with Epstein-Barr virus associated post-transplant lymphoproliferative disease.

Authors:  P S Randhawa; A Zeevi; C Alvares; S Gollin; R Agostini; E Yunis; S Saidman; L Contis; A J Demetris; M A Nalesnik
Journal:  In Vitro Cell Dev Biol Anim       Date:  1994-06       Impact factor: 2.416

Review 9.  Molecular pathology of AIDS-related lymphomas. Biologic aspects and clinicopathologic heterogeneity.

Authors:  G Gaidano; C Pastore; C Lanza; U Mazza; G Saglio
Journal:  Ann Hematol       Date:  1994-12       Impact factor: 3.673

Review 10.  Primary central nervous system lymphomas--an update.

Authors:  K A Jellinger; W Paulus
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.